

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-24 (canceled).

25 (new): A method of treating an autologous cell preparation for reinfusion into a patient, the method comprising contacting the preparation *ex vivo* with a recombinant replication-incompetent retrovirus containing a nucleic acid encoding a gene product of a wild type tumor suppressor gene, wherein the cell preparation comprises a mixed population of tumor cells deficient in the expression of the wild type tumor suppressor gene product and normal hematopoietic progenitor or blood cells, and wherein the contacting transduces the tumor cells to suppress the hyperproliferative phenotype of the tumor cells.

26 (new): The method of claim 25, wherein the contacting results in the death of the tumor cells.

27 (new): The method of claim 25, wherein the tumor cells are prostate cells, thyroid cells, breast cells, colon cells, lung cells, sarcoma cells, leukemic cells, or lymphoma cells.

28 (new): The method of claim 25, wherein said contacting is in the absence of selection for retroviral infection.

29. (new) The method of claim 28, wherein the tumor cells are prostate cells, thyroid cells, breast cells, colon cells, lung cells, sarcoma cells, leukemic cells, or lymphoma cells.

30. (new) The method of claim 25, wherein the tumor suppressor gene is a wild-type retinoblastoma tumor suppressor gene, Wilms tumor suppressor gene WT1 or colon carcinoma gene DCC.

31. (new) The method of claim 28, wherein the tumor suppressor gene is a wild-type retinoblastoma tumor suppressor gene, Wilms tumor suppressor gene WT1 or colon carcinoma gene DCC.